CO Relation between the CA 125 and Staging and Histopathological Type of Ovarian Cancer

Title: CO Relation between the CA 125 and Staging and Histopathological Type of Ovarian Cancer

Authors: Dr Ashwini Nayak U, Dr Chaitra Shivananjaiah, Dr Padma K, Dr Asha Swarup, Dr Amulya Cherukumudi, Dr Preetam Raj Chandran

DOI: http://dx.doi.org/10.18535/jmscr/v3i11.26

Abstract

Introduction: This study intends to find the correlation between CA125 and the staging and histopathology of ovarian tumours.

Methods: patients with ovarian tumours between January 2009 and January 2014 were included. Serum CA125 levels were noted. Ovarian tumor was staged using the FIGO staging system. The correlation between preoperative CA125 and staging and histopathology were evaluated. Chi square analysis was done and p value <0.05 was considered to be statistically significant.

Results: 106 ovarian cancer patients were included in the study period. the mean age was 47.5 ± 10.2 years.Preoperative CA125 level did not correlate significantly with the stage of ovarian cancer. Highest levels of CA 125 were found in serous tumours.Mean serum CA125 concentration in papillary serous adenocarcinoma patients (n = 45) was 1456±320 U/ml whereas in mucinous adenocarcinoma (n =24) 756 ±125 U/ml.

Conclusion: In our study, preoperative CA125levels does not correlate well with FIGO staging.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108

2. Consolidated Report of Population Based Cancer Registries 2001-200National Cancer Registry Program. Indian Council of Medical Research. Bangalore: 2006.

3. Hogdall E: Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 2008, 20:4-8.

4. Bast RC, Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC.Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68: 1331–1337.

5. Bast R, Klug T, St John E, et al. A radioummunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883-887.

6. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem. 1993;39:2509–2513

7. Rustin GJ, Nelstrop AE, Mclean P, et al:Defining response of ovarian carcinoma to initialchemotherapy according serum CA 125. J ClinOncol 14:1545-1551, 1996

8. Rustin GJ, Nelstrop AE, Tuxen MK, et al:Defining progression of ovarian carcinoma duringfollow-up according to CA 125: A North ThamesOvary Group study. Ann Oncol 7:361-364, 1996

9. Ind Tej, Iles R, Shephard JH, et al: Serumconcentration of cancer antigen 125, placentalalkaline phosphatase, cancer associated serumantigen and free beta human chorionic gonadotrophinas prognostic markers for epithelial ovariancancer. Br J Obstet Gynaecol 104:1024-1029.

10. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer2000; 82: 1535–1538.

11. Jacobs and R. C. Bast Jr., “The CA 125 tumour-associated antigen: a review of the literature,” Human Reproduction, vol. 4, no. 1, pp. 1–12, 1989.

12. Bairey O, Blickstein D, Stark P.Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma, Leuk Lymphoma. 2003 Oct;44(10):1733-8.

13. Nathalie Scholler and Nicole Urban CA125 in Ovarian Cancer Biomark Med. 2007 Dec; 1(4): 513–523.

14. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Hogdall CK. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol. 2007;104:508–515.

15. Jones III OW, Surwit EA. Meigs’ syndrome and elevated CA125. Obstet Gynecol 1989;73:520–1

16. Viren Asher, Robert Hammond, and Tim J Duncan. Pelvic mass associated with raised CA 125 for benign condition: a case report.World J Surg Oncol. 2010; 8: 28.

17. Kolwijick, E. et al. Preoperative CA-125 level in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. Int J Gynecol Cancer, v. 19, n. 8, p. 1335-8, 2009.

18. Eduardo Cambruzzi; Rosane de Lima; Simone Luís Teixeira et al. The relationship between serum levels of CA 125 and the degree of differentiation in ovarian neoplasmsJ Bras Patol Med Lab, v. 50, n. 1, p. 20-25, Fevereiro 2014.

19. B. C. Cooper, A. K. Sood, C. S. Davis et al., “Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer,” Obstetrics and Gynecology, vol. 100, no. 1, pp. 59–64, 2002

20. V. Thakur, A.K. Anand , U. Mukherjee Determination of cancer antigen 125 in ovarian carcinoma Indian Journal of Clinical Biochemistry, 2003, 18 (2) 27-33

21. Munstedt, K., Krisch, M., Sachsse, S. andVahrson, H. (1997). Serum CA125 levels andsurvival in advanced ovarian cancer. Arch.Gynecol. Veslet. 259, 117-123.

22. N. Osman, N. O'Leary, M. J. Higgins et al. Correlation of serum CA125 levels with stage, grade and survival of patients with epithelial ovarian cancer Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 25, No 18S (June 20 Supplement), 2007: 16066

Corresponding Author

Dr Chaitra Shivananjaiah

Junior Resident (OBG),

M.S.Ramaiah Medical College, Bangalore, India